Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.57 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8441624 | 0.91 | SLC6A4 (0.54) | SLC6A4SLC6A9ALDH1A1CYP2D6MAPT | |
| SCHEMBL6004115 | 0.91 | SLC6A9 (0.59) | SLC6A4SLC6A9ALDH1A1CYP2D6MAPT | |
| SCHEMBL6005405 | 0.91 | SLC6A9 (0.59) | SLC6A4SLC6A9ALDH1A1CYP2D6MAPT | |
| SCHEMBL6006253 | 0.91 | SLC6A9 (0.59) | SLC6A4SLC6A9ALDH1A1CYP2D6MAPT | |
| SCHEMBL6004073 | 0.88 | SLC6A4 (0.61) | SLC6A4CYP2D6CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL8202643 | 0.88 | SLC6A4 (0.61) | SLC6A4CYP2D6CYP2C9CYP2C19SLC6A2 | |
| SCHEMBL27422903 | 0.86 | SLC6A4 (0.57) | SLC6A4SLC6A9ALDH1A1CYP2D6MAPT | |
| SCHEMBL6005399 | 0.85 | SLC6A4 (0.59) | SLC6A4SLC6A9SLC6A2SLC6A3HTR1A | |
| SCHEMBL6004141 | 0.84 | SLC6A4 (0.51) | SLC6A4SLC6A9ALDH1A1CYP2D6MAPT | |
| SCHEMBL6007102 | 0.83 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1014966-A4 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1014966-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Allelix Neuroscience Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1997045115-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | TROPHIX PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | SLC6A4 9/4885SLC6A9 58/4885ALDH1A1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.